Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NRG1 fusion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

NRG1 fusion	Solid Tumor	NRG1 fusion	Solid Tumor	MCLA-128 Sensitive: B - Late Trials MCLA-128 Sensitive : B	MCLA-128 Sensitive: B - Late Trials MCLA-128 Sensitive : B
NRG1 fusion	Solid Tumor	NRG1 fusion	Solid Tumor	MM-121 Sensitive: B - Late Trials MM-121 Sensitive : B	MM-121 Sensitive: B - Late Trials MM-121 Sensitive : B
NRG1 fusion	Pancreatic Cancer	NRG1 fusion	Pancreatic Cancer	MCLA-128 Sensitive: B - Late Trials MCLA-128 Sensitive : B	MCLA-128 Sensitive: B - Late Trials MCLA-128 Sensitive : B
NRG1 fusion	Non Small Cell Lung Cancer	NRG1 fusion	Non Small Cell Lung Cancer	MCLA-128 Sensitive: B - Late Trials MCLA-128 Sensitive : B	MCLA-128 Sensitive: B - Late Trials MCLA-128 Sensitive : B
NRG1 fusion	Pancreatic Ductal Adenocarcinoma	NRG1 fusion	Pancreatic Ductal Adenocarcinoma	MCLA-128 Sensitive: B - Late Trials MCLA-128 Sensitive : B	MCLA-128 Sensitive: B - Late Trials MCLA-128 Sensitive : B
NRG1 fusion	Lung Cancer	NRG1 fusion	Lung Cancer	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2
NRG1 fusion	Solid Tumor	NRG1 fusion	Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
NRG1 fusion	Ovarian Cancer	NRG1 fusion	Ovarian Cancer	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2	MM-121 Sensitive: C2 – Inclusion Criteria MM-121 Sensitive : C2
NRG1 fusion	Cholangiocarcinoma	NRG1 fusion	Cholangiocarcinoma	MCLA-128 Sensitive: C2 – Inclusion Criteria MCLA-128 Sensitive : C2	MCLA-128 Sensitive: C2 – Inclusion Criteria MCLA-128 Sensitive : C2
NRG1 fusion	Breast Cancer	NRG1 fusion	Breast Cancer	MCLA-128 Sensitive: C2 – Inclusion Criteria MCLA-128 Sensitive : C2	MCLA-128 Sensitive: C2 – Inclusion Criteria MCLA-128 Sensitive : C2
NRG1 fusion	Pancreatic Cancer	NRG1 fusion	Pancreatic Cancer	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3